Lin C Y
Department of Medical Research, Veterans General Hospital, Taipei, Taiwan, Republic of China.
Kidney Int Suppl. 1991 Dec;35:S46-53.
To evaluate the clinical features, immunopathology and the prognosis of hepatitis B virus-associated membranous nephropathy (HBVMN), 34 patients (25 boys and 9 girls) from April 1981 to November 1986 were studied. With Fab fragments of monoclonal antibodies, hepatitis B e antigen (HBeAg) was detected in the glomerular deposits from 30 cases (88.2%) and in the sera from 32 cases (94.1%). These results suggest that HBe Ag plays an important role in the development of HBVMN. In patients without corticosteroid treatment, HBV DNA was found as only episomal molecules with 3.2 kb in macrophage, T and B cells. The HBV cellular DNA disappeared within 12 months. In a HBVMN patient with corticosteroid treatment, even three years later, cellular HBV DNA was still detectable in T cells. They also had occasional proteinuria. From the in vitro study, we also demonstrated that corticosteroid stimulated endogenous HBsAg and HBeAg production from patient's mononuclear cells. Therefore, the use of corticosteroid could lead to a potential risk of enhancing viral replication. In addition, clinical trials of 32 cases demonstrate a relatively poor response to the steroid therapy with persistent heavy proteinuria (32.4%) or a high frequent relapse rate (38.2%); only one case (3.1%) had early response. Four cases received follow-up renal biopsy, progressive sclerosis with interstitial fibrosis being noted in each instance. The stage of membranous nephropathy in light microscope had progressed from stage I or II into III. One had impaired renal function. Therefore, HBVMN does not always take a benign course. Usage of corticosteroid in HBVMN patients should be avoided.
为评估乙型肝炎病毒相关性膜性肾病(HBVMN)的临床特征、免疫病理学及预后,对1981年4月至1986年11月期间的34例患者(25例男孩和9例女孩)进行了研究。采用单克隆抗体的Fab片段,在30例患者(88.2%)的肾小球沉积物及32例患者(94.1%)的血清中检测到乙型肝炎e抗原(HBeAg)。这些结果表明,HBeAg在HBVMN的发病机制中起重要作用。在未接受皮质类固醇治疗的患者中,HBV DNA仅以3.2 kb的游离分子形式存在于巨噬细胞、T细胞和B细胞中。HBV细胞内DNA在12个月内消失。在一名接受皮质类固醇治疗的HBVMN患者中,即使三年后,仍可在T细胞中检测到细胞内HBV DNA。他们偶尔也有蛋白尿。体外研究还表明,皮质类固醇可刺激患者单核细胞产生内源性HBsAg和HBeAg。因此,使用皮质类固醇可能会导致病毒复制增强的潜在风险。此外,32例患者的临床试验表明,类固醇治疗反应相对较差,持续性大量蛋白尿(32.4%)或高复发率(38.2%);只有1例(3.1%)有早期反应。4例患者接受了随访肾活检,每例均发现进行性硬化伴间质纤维化。光镜下膜性肾病的分期已从I期或II期进展为III期。1例患者肾功能受损。因此,HBVMN并非总是良性病程。应避免在HBVMN患者中使用皮质类固醇。